Immix Biopharma | Investor Presentation Deck | 60 slides · page 41 of 60
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.
Pitch deck · comparison_table · compare_peers · balanced density
Slide locked Sign in to view
Slide schematic 4/4
image 1/1 source-note 1/1 table 1/1 title 1/1
Components 4
logo source-note data headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.